MYCN is altered in 22.47% of neuroblastoma patients with MYCN Amplification present in 22.87% of all neuroblastoma patients [4].

MYCN Amplification is an inclusion criterion in 20 clinical trials for neuroblastoma, of which 16 are open and 4 are closed. Of the trials that contain MYCN Amplification and neuroblastoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (4 open), 3 are phase 3 (3 open), and 4 are no phase specified (2 open) [5].

MYCN is altered in 1.84% of medulloblastoma patients with MYCN Amplification present in 3.41% of all medulloblastoma patients [4].

MYCN Amplification is an inclusion criterion in 12 clinical trials for medulloblastoma, of which 12 are open and 0 are closed. Of the trials that contain MYCN Amplification and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [5].

MYCN is altered in 1.51% of malignant solid tumor patients with MYCN Amplification present in 0.45% of all malignant solid tumor patients [4].

MYCN Amplification is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain MYCN Amplification and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open) [5].

MYCN Amplification is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain MYCN Amplification and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

MYCN is altered in 5.41% of ependymoma patients with MYCN Amplification present in 6.25% of all ependymoma patients [4].

MYCN Amplification is an inclusion criterion in 3 clinical trials for ependymoma, of which 3 are open and 0 are closed. Of the trials that contain MYCN Amplification and ependymoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

MYCN is altered in 1.01% of soft tissue sarcoma patients with MYCN Amplification present in 0.7% of all soft tissue sarcoma patients [4].

MYCN Amplification is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain MYCN Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 3 clinical trials for desmoplastic small round cell tumor, of which 3 are open and 0 are closed. Of the trials that contain MYCN Amplification and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

MYCN is altered in 1.72% of central nervous system embryonal neoplasm patients with MYCN Amplification present in 3.15% of all central nervous system embryonal neoplasm patients [4].

MYCN Amplification is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYCN is altered in 2.32% of malignant glioma patients with MYCN Amplification present in 1.76% of all malignant glioma patients [4].

MYCN Amplification is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 3.74% of melanoma patients with MYCN Amplification present in 0.05% of all melanoma patients [4].

MYCN Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for embryonal tumor with multilayered rosettes, C19MC-altered, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYCN is altered in 0.79% of osteosarcoma patients [4].

MYCN Amplification is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN Amplification and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 15.0% of alveolar rhabdomyosarcoma patients with MYCN Amplification present in 16.67% of all alveolar rhabdomyosarcoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for alveolar rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and alveolar rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 9.64% of kidney Wilms tumor patients with MYCN Amplification present in 3.9% of all kidney Wilms tumor patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for kidney Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and kidney Wilms tumor as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN is altered in 9.64% of Wilms tumor patients with MYCN Amplification present in 3.9% of all Wilms tumor patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and Wilms tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 4.35% of high-grade glioma, NOS patients with MYCN Amplification present in 3.21% of all high-grade glioma, NOS patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN is altered in 3.09% of anaplastic astrocytoma patients with MYCN Amplification present in 2.55% of all anaplastic astrocytoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN is altered in 2.24% of glioblastoma patients with MYCN Amplification present in 1.72% of all glioblastoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN is altered in 2.1% of diffuse glioma patients with MYCN Amplification present in 1.52% of all diffuse glioma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN is altered in 2.02% of glioma patients with MYCN Amplification present in 1.52% of all glioma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and glioma as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN is altered in 1.2% of retinoblastoma patients with MYCN Amplification present in 1.41% of all retinoblastoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and retinoblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 1.76% of germ cell tumor patients with MYCN Amplification present in 1.4% of all germ cell tumor patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and germ cell tumor as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN is altered in 1.82% of central nervous system neoplasm patients with MYCN Amplification present in 1.38% of all central nervous system neoplasm patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and central nervous system neoplasm as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN is altered in 2.18% of small cell lung carcinoma patients with MYCN Amplification present in 1.14% of all small cell lung carcinoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

MYCN is altered in 0.91% of lymphoma patients with MYCN Amplification present in 0.05% of all lymphoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN is altered in 1.24% of anaplastic oligodendroglioma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for childhood central nervous system embryonal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and childhood central nervous system embryonal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for choroid plexus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and choroid plexus neoplasm as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for craniopharyngioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and craniopharyngioma as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 1.16% of diffuse large B-cell lymphoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and double-hit lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and Ewing sarcoma as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 0.94% of fibrosarcoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for fibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and fibrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 0.31% of follicular lymphoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and ganglioneuroblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for ganglioneuroblastoma, intermixed, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and ganglioneuroblastoma, intermixed as inclusion criteria, 1 is phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for ganglioneuroblastoma, nodular, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and ganglioneuroblastoma, nodular as inclusion criteria, 1 is phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

MYCN is altered in 1.09% of leiomyosarcoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and leiomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 0.22% of liposarcoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 1.13% of mantle cell lymphoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN is altered in 0.78% of mature B-cell non-hodgkin lymphoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN is altered in 0.53% of meningioma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and meningioma as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for neuroectodermal tumor of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and neuroectodermal tumor of soft tissue as inclusion criteria, 1 is no phase specified (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN Amplification and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for spindle cell sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and spindle cell sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN Amplification is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and synovial sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYCN is altered in 1.33% of undifferentiated pleomorphic sarcoma patients [4].

MYCN Amplification is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN Amplification and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].